The article deals with a problem of combined use of interferon (laferon) and interleukine in patients with skin melanoma. Recombinant interleukin-2 (rlL-2) was included into the worked-out scheme. Patients with primarylocalized skin melanoma (T(2-4)N0M0) have been studied. Three groups were chosen. 901 patients of the control group underwent excision of tumor (e/t); 34 patients of the first study group (e/1) were given endolymphatic interferontherapy (ift); 35 patients of the second study group were subjected to excision of tumor followed by endolymphatic interferontherapy. One-year relapse-free survival among patients of the control group reached <$E 57,6~symbol С~1,6> %, 1st study group - <$E 70,5~symbol С~7,8> % and 2nd study group - <$E 836~symbol С~6,7> %. Total one-year survival among patients of the control group was <$E 92,1~symbol С~0,9> %, in the 1st study group - <$E 97,0~symbol С~2,9> %, in the 2nd study group - <$E 92,7~symbol С~5,0> %. Thus, the combined use of recombinant interferon (laferon and interleukin (ronkoleukin)) intreatment schemes of malignant skin melanoma was proved to be perspective.

  Якщо, ви не знайшли інформацію про автора(ів) публікації, маєте бажання виправити або відобразити більш докладну інформацію про науковців України запрошуємо заповнити "Анкету науковця"